Baseline Demographic and Clinical Characteristics of Patients With Chronic HCV Genotype 1 Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin, Stratified by Receipt of Opioid Substitution Therapy
| Characteristic . | Receiving OST (n = 149) . | Not Receiving OST (n = 4598) . |
|---|---|---|
| Male, No. (%) | 112 (75) | 2639 (57) |
| Caucasian, No. (%) | 140 (94) | 4177 (91) |
| Age, median (range), y | 49 (19–69) | 54 (18–83) |
| BMI, median (range), kg/m2 | 26 (16–45) | 26 (16–52) |
| Geographic region, No. (%) | ||
| North America | 92 (62) | 1968 (43) |
| Europe | 53 (36) | 2453 (53) |
| Australia/New Zealand | 0 | 44 (1) |
| Asia | 0 | 51 (1) |
| Tobacco use (current), No. (%)a | 108 (72) | 1367 (30) |
| Alcohol use (current), No. (%)b | 37 (25) | 1368 (30) |
| History of injecting drug use, No. (%)c | ||
| Yes | 58 (39) | 859 (19) |
| No | 10 (7) | 1592 (35) |
| Missing | 81 (54) | 2142 (47) |
| HCV GT1 subtype, No. (%) | ||
| 1a | 122 (82) | 2409 (52) |
| 1b | 27 (18) | 2189 (48) |
| IFNL3 (IL28B) non-CC genotype, No. (%)d | 98 (66) | 3568 (78) |
| Baseline HCV ≥800 000 log10 IU/mL, No. (%)e | 114 (77) | 3526 (77) |
| Treatment naïve, No. (%) | 113 (76) | 2792 (61) |
| HIV infection, No. (%) | 18 (12) | 271 (6) |
| Fibrosis stage, No. (%)f | ||
| F0–F1 | 84 (56) | 2599 (57) |
| F2 | 22 (15) | 618 (13) |
| F3 | 18 (12) | 547 (12) |
| F4 | 25 (17) | 830 (18) |
| Therapy | ||
| DAA + RBV | 138 (93) | 3071 (67) |
| DAA | 11 (7) | 1527 (33) |
| Characteristic . | Receiving OST (n = 149) . | Not Receiving OST (n = 4598) . |
|---|---|---|
| Male, No. (%) | 112 (75) | 2639 (57) |
| Caucasian, No. (%) | 140 (94) | 4177 (91) |
| Age, median (range), y | 49 (19–69) | 54 (18–83) |
| BMI, median (range), kg/m2 | 26 (16–45) | 26 (16–52) |
| Geographic region, No. (%) | ||
| North America | 92 (62) | 1968 (43) |
| Europe | 53 (36) | 2453 (53) |
| Australia/New Zealand | 0 | 44 (1) |
| Asia | 0 | 51 (1) |
| Tobacco use (current), No. (%)a | 108 (72) | 1367 (30) |
| Alcohol use (current), No. (%)b | 37 (25) | 1368 (30) |
| History of injecting drug use, No. (%)c | ||
| Yes | 58 (39) | 859 (19) |
| No | 10 (7) | 1592 (35) |
| Missing | 81 (54) | 2142 (47) |
| HCV GT1 subtype, No. (%) | ||
| 1a | 122 (82) | 2409 (52) |
| 1b | 27 (18) | 2189 (48) |
| IFNL3 (IL28B) non-CC genotype, No. (%)d | 98 (66) | 3568 (78) |
| Baseline HCV ≥800 000 log10 IU/mL, No. (%)e | 114 (77) | 3526 (77) |
| Treatment naïve, No. (%) | 113 (76) | 2792 (61) |
| HIV infection, No. (%) | 18 (12) | 271 (6) |
| Fibrosis stage, No. (%)f | ||
| F0–F1 | 84 (56) | 2599 (57) |
| F2 | 22 (15) | 618 (13) |
| F3 | 18 (12) | 547 (12) |
| F4 | 25 (17) | 830 (18) |
| Therapy | ||
| DAA + RBV | 138 (93) | 3071 (67) |
| DAA | 11 (7) | 1527 (33) |
Abbreviations: BMI, body mass index; DAA, direct-acting antiviral; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin-28B gene; OST, opioid substitution therapy; RBV, ribavirin.
aTobacco use was unknown for 20 patients (0.4%) who were not receiving OST.
bAlcohol use was unknown for 1 (0.7%) and 54 patients (1%) among those receiving OST and those not receiving OST, respectively.
cFormer injection drug use information was not collected in 2 of the 12 studies included in this analysis.
dIFNL3 genotype was missing for 1 (0.7%) and 20 patients (0.4%) among those receiving OST and those not receiving OST, respectively.
eBaseline HCV RNA was missing for 3 patients (0.07%) who were not receiving OST.
fBaseline fibrosis stage was missing for 4 patients (0.09%) who were not receiving OST. Fibrosis stage was determined using the results of a liver biopsy, FibroScan, or FibroTest/aspartate aminotransferase to platelet ratio index.
Baseline Demographic and Clinical Characteristics of Patients With Chronic HCV Genotype 1 Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin, Stratified by Receipt of Opioid Substitution Therapy
| Characteristic . | Receiving OST (n = 149) . | Not Receiving OST (n = 4598) . |
|---|---|---|
| Male, No. (%) | 112 (75) | 2639 (57) |
| Caucasian, No. (%) | 140 (94) | 4177 (91) |
| Age, median (range), y | 49 (19–69) | 54 (18–83) |
| BMI, median (range), kg/m2 | 26 (16–45) | 26 (16–52) |
| Geographic region, No. (%) | ||
| North America | 92 (62) | 1968 (43) |
| Europe | 53 (36) | 2453 (53) |
| Australia/New Zealand | 0 | 44 (1) |
| Asia | 0 | 51 (1) |
| Tobacco use (current), No. (%)a | 108 (72) | 1367 (30) |
| Alcohol use (current), No. (%)b | 37 (25) | 1368 (30) |
| History of injecting drug use, No. (%)c | ||
| Yes | 58 (39) | 859 (19) |
| No | 10 (7) | 1592 (35) |
| Missing | 81 (54) | 2142 (47) |
| HCV GT1 subtype, No. (%) | ||
| 1a | 122 (82) | 2409 (52) |
| 1b | 27 (18) | 2189 (48) |
| IFNL3 (IL28B) non-CC genotype, No. (%)d | 98 (66) | 3568 (78) |
| Baseline HCV ≥800 000 log10 IU/mL, No. (%)e | 114 (77) | 3526 (77) |
| Treatment naïve, No. (%) | 113 (76) | 2792 (61) |
| HIV infection, No. (%) | 18 (12) | 271 (6) |
| Fibrosis stage, No. (%)f | ||
| F0–F1 | 84 (56) | 2599 (57) |
| F2 | 22 (15) | 618 (13) |
| F3 | 18 (12) | 547 (12) |
| F4 | 25 (17) | 830 (18) |
| Therapy | ||
| DAA + RBV | 138 (93) | 3071 (67) |
| DAA | 11 (7) | 1527 (33) |
| Characteristic . | Receiving OST (n = 149) . | Not Receiving OST (n = 4598) . |
|---|---|---|
| Male, No. (%) | 112 (75) | 2639 (57) |
| Caucasian, No. (%) | 140 (94) | 4177 (91) |
| Age, median (range), y | 49 (19–69) | 54 (18–83) |
| BMI, median (range), kg/m2 | 26 (16–45) | 26 (16–52) |
| Geographic region, No. (%) | ||
| North America | 92 (62) | 1968 (43) |
| Europe | 53 (36) | 2453 (53) |
| Australia/New Zealand | 0 | 44 (1) |
| Asia | 0 | 51 (1) |
| Tobacco use (current), No. (%)a | 108 (72) | 1367 (30) |
| Alcohol use (current), No. (%)b | 37 (25) | 1368 (30) |
| History of injecting drug use, No. (%)c | ||
| Yes | 58 (39) | 859 (19) |
| No | 10 (7) | 1592 (35) |
| Missing | 81 (54) | 2142 (47) |
| HCV GT1 subtype, No. (%) | ||
| 1a | 122 (82) | 2409 (52) |
| 1b | 27 (18) | 2189 (48) |
| IFNL3 (IL28B) non-CC genotype, No. (%)d | 98 (66) | 3568 (78) |
| Baseline HCV ≥800 000 log10 IU/mL, No. (%)e | 114 (77) | 3526 (77) |
| Treatment naïve, No. (%) | 113 (76) | 2792 (61) |
| HIV infection, No. (%) | 18 (12) | 271 (6) |
| Fibrosis stage, No. (%)f | ||
| F0–F1 | 84 (56) | 2599 (57) |
| F2 | 22 (15) | 618 (13) |
| F3 | 18 (12) | 547 (12) |
| F4 | 25 (17) | 830 (18) |
| Therapy | ||
| DAA + RBV | 138 (93) | 3071 (67) |
| DAA | 11 (7) | 1527 (33) |
Abbreviations: BMI, body mass index; DAA, direct-acting antiviral; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin-28B gene; OST, opioid substitution therapy; RBV, ribavirin.
aTobacco use was unknown for 20 patients (0.4%) who were not receiving OST.
bAlcohol use was unknown for 1 (0.7%) and 54 patients (1%) among those receiving OST and those not receiving OST, respectively.
cFormer injection drug use information was not collected in 2 of the 12 studies included in this analysis.
dIFNL3 genotype was missing for 1 (0.7%) and 20 patients (0.4%) among those receiving OST and those not receiving OST, respectively.
eBaseline HCV RNA was missing for 3 patients (0.07%) who were not receiving OST.
fBaseline fibrosis stage was missing for 4 patients (0.09%) who were not receiving OST. Fibrosis stage was determined using the results of a liver biopsy, FibroScan, or FibroTest/aspartate aminotransferase to platelet ratio index.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
